Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ARCHIVE
ARCHIVE
- Taiho Ties Up with Nordic Group to Commercialize TS-1 in Europe
August 1, 2011
- PMDA Establishes Coordinating Organization to Prepare for PIC/S Membership
August 1, 2011
- Eisai's Halaven “Extremely Convenient for Outpatients”: Dr Iwata of Aichi Cancer Center
August 1, 2011
- Equa Ranked No. 1 Both in HP, GP Markets for 2nd Straight Month: RepTrack Survey
August 1, 2011
- Generic Drugmakers Still Reluctant to File for Add'l Indications Based on Info in Public Domain
August 1, 2011
- JPA Urges Member Pharmacies to Participate in JCQHC-initiated Accident Reporting Project
August 1, 2011
- Japanese Pharm. Industry Needs Aggressive Globalization: Dr Kato of EFPIA Japan
August 1, 2011
- Premium for New Drug Development Should Be Made Permanent: Mr Wolf of PhRMA
August 1, 2011
- Asahi Kasei to Enter Market for Medical Devices for Emergency Care Aiming at ¥100 Bil. Sales
August 1, 2011
- Shionogi to Acquire 9 Products from Victory Pharma of the US
August 1, 2011
- FDA's Advisory Committee Does Not Recommend Approval of Dapagliflozin
August 1, 2011
- Korosho, PMDA Providing Risk Info on Drugs Under Review on Websites
August 1, 2011
- LTT Bio-Pharma to License Inhalant PC-SOD to CKD in South Korea
August 1, 2011
- Transfer of Part of PMDA Functions to Osaka Proposed in Kansai Sogo Tokku Plan
August 1, 2011
- Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
August 1, 2011
- Chugai Applies for Approval of Pulmozyme for Cystic Fibrosis
August 1, 2011
- Mochida, MTPC to Launch Lexapro on Aug. 22
August 1, 2011
- Sodium Phenylbutyrate from CMIC Designated as Orphan Drug
August 1, 2011
- BMKK to Take the Offensive with 1st-line CML Treatment Sprycel
July 25, 2011
- Combinational Use of Avastin, Xeloda Approved in Europe: Roche
July 25, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…